Stock Events

Stock Events

Insight Molecular Diagnostics 

$4.16
25
+$0.04+0.97% Friday 19:59
-$0.03-0.72%Friday 21:17After hours

Statistics

Day High
4.16
Day Low
4.12
52W High
8.48
52W Low
2.47
Volume
6,982
Avg. Volume
-
Mkt Cap
136.13M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.31
-0.25
-0.18
-0.12
Expected EPS
-0.2323
Actual EPS
N/A

Financials

-1,238.52%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
4.06MRevenue
-50.22MNet Income

Analyst Ratings

8.50Average Price Target
The highest estimate is 9.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow IMDX. It's not an investment recommendation.
LENZ Therapeutics
2
LENZ
Neuronetics
2
STIM

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Guardant Health
GH
Mkt Cap21.67B
Fulgent Genetics
FLGT
Mkt Cap539.57M
Fulgent Genetics offers comprehensive genetic testing, including for cancer, competing in the genetic testing market.
Bionano Genomics
BNGO
Mkt Cap13.78M
Bionano Genomics provides genomic analysis solutions, competing in the genetic diagnostics space relevant to oncology.
Pacific Biosciences of California
PACB
Mkt Cap435.16M
Pacific Biosciences offers sequencing solutions that can be used in cancer research and diagnostics, competing in the genomic analysis market.
Illumina
ILMN
Mkt Cap32.55B
Illumina provides sequencing and array-based solutions for genetic analysis, directly competing in the genomics and diagnostics field.
CRISPR Therapeutics
CRSP
Mkt Cap5.58B
CRISPR Therapeutics engages in gene editing, which has applications in cancer treatment and diagnostics, presenting an indirect competition.
Natera
NTRA
Mkt Cap47.03B
Natera offers genetic testing, including for cancer, competing in the personalized medicine and diagnostics market.

About

Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
Show more...
CEO
Joshua Riggs
Employees
58
Country
United States
ISIN
US68235C2061
WKN
000A3EQV9

Listings

XNAS
US
IMDX
STU
DE
7OC0.STU
MU
DE
7OC0.MU
STU
DE
7OC.STU

0 Comments

Share your thoughts

FAQ

What is Insight Molecular Diagnostics stock price today?▼
The current price of IMDX is $4.16 USD — it has increased by +0.97% in the past 24 hours. Watch Insight Molecular Diagnostics stock price performance more closely on the chart.
What is Insight Molecular Diagnostics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Insight Molecular Diagnostics stocks are traded under the ticker IMDX.
Is Insight Molecular Diagnostics stock price growing?▼
IMDX stock has risen by +0.73% compared to the previous week, the month change is a -16.8% fall, over the last year Insight Molecular Diagnostics has showed a +67.74% increase.
What is Insight Molecular Diagnostics market cap?▼
Today Insight Molecular Diagnostics has the market capitalization of 136.13M
When is the next Insight Molecular Diagnostics earnings date?▼
Insight Molecular Diagnostics is going to release the next earnings report on November 05, 2026.
What were Insight Molecular Diagnostics earnings last quarter?▼
IMDX earnings for the last quarter are -0.31 USD per share, whereas the estimation was -0.25 USD resulting in a -22.07% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Insight Molecular Diagnostics revenue for the last year?▼
Insight Molecular Diagnostics revenue for the last year amounts to 4.06M USD.
What is Insight Molecular Diagnostics net income for the last year?▼
IMDX net income for the last year is -50.22M USD.
How many employees does Insight Molecular Diagnostics have?▼
As of September 05, 2026, the company has 58 employees.
In which sector is Insight Molecular Diagnostics located?▼
Insight Molecular Diagnostics operates in the Health & Wellness sector.
When did Insight Molecular Diagnostics complete a stock split?▼
The last stock split for Insight Molecular Diagnostics was on July 25, 2023 with a ratio of 1:20.
Where is Insight Molecular Diagnostics headquartered?▼
Insight Molecular Diagnostics is headquartered in NASHVILLE, United States.